Roche
NEWS
Eisai and Biogen’s BLA for lecanemab for Alzheimer’s disease received FDA Priority Review with a target action date of January 6, 2023, while Roche’s lymphoma drug scored the same designation.
The Roche Accelerator is designed to help companies bridge the gap between idea and proof-of-concept. It is one of several incubators recently founded by Western companies.
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
The WHO reports it’s too early to tell if the monkeypox outbreak could become a pandemic, but believe there is a window of opportunity to control the cases.
The long weekend saw BMS’s Opdivo, Novartis’s Kymriah and Roche’s Evrysdi win FDA approvals in new indications.
A roundup of last week’s top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Warnings of Monkeypox went unheeded as scientists around the world began to uncover clues about the disease’s origin. Here are the latest updates on the monkeypox virus.
Two months after closing its Series A financing round, KaliVir Immunotherapeutics forged an exclusive licensing and collaboration agreement with Roche.
JOBS
IN THE PRESS